new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp A Corporation A Subsidiary Of Merck x26 Co Inc
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors




Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15 Mono- and di-peg il-10 production; and uses
22015001159001/08/15 Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12 Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12 Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52016003188202/04/16  new patent  Imidazopyridyl compounds as aldosterone synthase inhibitors
62016002409101/28/16 Inhibitors of the renal outer medullary potassium channel
72016002410001/28/16 Process for preparing chiral dipeptidyl peptidase-iv inhibitors
82016001692101/21/16 S-imino-s-oxo-iminothiazine compounds as bace inhibitors, compositions, and their use
92016001692301/21/16 S-imino-s-oxo-iminothiadiazine compounds as bace inhibitors, compositions, and their use
102016001693501/21/16 2-pyridyloxy-4-ether orexin receptor antagonists
112016001694701/21/16 Substituted pyridizinone derivatives as pde10 inhibitors
122016001697501/21/16 C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
132016001703601/21/16 Cell line 3m
142016000836101/14/16 Compositions and methods for treating cancer
152016000968101/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
162016000968201/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
172016000968901/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
182016000969601/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
192016000072101/07/16 Gastro-retentive formulations
202016000092101/07/16 Ceftolozane antibiotic compositions
212016000222401/07/16 Novel indole derivatives useful as anti-diabetic agents
222016000225501/07/16 Antidiabetic bicyclic compounds
232016000225901/07/16 Inhibitors of the renal outer medullary potassium channel
242015037479512/31/15 O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
252015037624912/31/15 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
262015036824612/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
272015036824712/24/15 2,6,7 substituted purines as hdm2 inhibitors
282015036826512/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
292015036826912/24/15 Factor ixa inhibitors
302015036834412/24/15 Mdl-1 ligand
312015036868212/24/15 Immobilized transaminases and process for making and using immobilized transaminase
322015035979312/17/15 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
332015036109812/17/15 Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
342015036110112/17/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
352015035349812/10/15 Substituted isoquinolines as crth2 receptor modulators
362015035351612/10/15 Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as bace inhibitors, compositions, and their use
372015035353512/10/15 Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
382015035355212/10/15 Purine inhibitors of human phosphatidylinositol 3-kinase delta
392015035355312/10/15 2,6,7,8 substituted purines as hdm2 inhibitors
402015035356512/10/15 Btk inhibitors
412015035357012/10/15 Btk inhibitors
422015035518412/10/15 Antibodies that bind to human programmed death ligand 1 (pd-l1)
432015034293112/03/15 Spirocyclic cetp inhibitors
442015034315312/03/15 Dual chamber mixing syringes and methods of using same
452015034315712/03/15 Medication injector with near-empty alert
462015034448712/03/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
472015034450012/03/15 C2,c6 oxacyclic-fused thiazine dioxide compounds as bace inhibitors, compositions, and their use
482015033564811/26/15 Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases
492015033694611/26/15 Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
502015033694811/26/15 Isotopically labeled biaryl urea compounds
512015033699111/26/15 Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
522015033701311/26/15 Novel antibacterial agents for the treatment of gram positive infections
532015033727411/26/15 Pmt2-, och1-, pmt5- mutant cells
542015032952111/19/15 Process for making reverse transcriptase inhibitors
552015032953111/19/15 Amino-pyrimidine-containing spleen tyrosine kinase (syk) inhibitors
562015032953911/19/15 4-pyridinonetriazine derivatives as hiv integrase inhibitors
572015032954811/19/15 Substituted pyrrolopyrimidines as hdm2 inhibitors
582015032955711/19/15 Inhibitors of the renal outer medullary potassium channel
592015032956211/19/15 Factor ixa inhibitors
602015032961211/19/15 Process for purifying insulin and analogues thereof
612015032962811/19/15 Liquid formulations for an anti-tnf alpha antibody
622015032963211/19/15 Solution formulations of engineered anti-il-23p19 antibodies
632015032072411/12/15 Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
642015032073311/12/15 Indazole compounds as aldosterone synthase inhibitors
652015032086011/12/15 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
662015032203911/12/15 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
672015032204011/12/15 3-ester-4 substituted orexin receptor antagonists
682015032204111/12/15 2-pyridyloxy-4-nitrile-4-substituted orexin receptor antagonists
692015032205611/12/15 Factor ixa inhibitors
702015032207411/12/15 4-fluoropiperidine orexin receptor antagonists
712015032251911/12/15 Biomarkers for psoriasis treatment response
722015031522111/05/15 Nucleoside kinase bypass compositions and methods
732015031392611/05/15 Syn3 compositions and methods
742015031514111/05/15 Thrombin inhibitors
752015031522111/05/15 Nucleoside kinase bypass compositions and methods
762015031522611/05/15 Disulfide masked prodrug compositions and methods
772015030609110/29/15 Aldosterone synthase inhibitors
782015030746410/29/15 Therapeutic thiazolidinone compounds
792015030746510/29/15 Iminothiadiazine dioxide compounds as bace inhibitors, compositions and their use
802015030747910/29/15 Cyclobutyl benzimidazoles as pde 10 inhibitors
812015030748810/29/15 Cyclopropyl imidazopyridine pde10 inhibitors
822015030748910/29/15 Pyrimidine pde10 inhibitors
832015030753310/29/15 Spirocyclic sulfones as gamma secretase inhibitors
842015030758010/29/15 Oxyntomodulin analogs
852015030759110/29/15 On-column refolding and purifying of lipoproteins
862015030760610/29/15 Lyophilized spherical pellets of anti-il-23 antibodies
872015030785010/29/15 Conditional replicating viral vectors
882015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
892015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
902015029756610/22/15 Rorgammat inhibitors
912015029912210/22/15 Glycosidase inhibitors and uses thereof
922015029912510/22/15 Prodrug bipyridylaminopyridines as syk inhibitors
932015029916710/22/15 Regioselective n-2 arylation of indazoles
942015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
952015029922410/22/15 Inhibitors of irak4 activity
962015029922710/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
972015029924310/22/15 2'-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
982015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
992015029969010/22/15 Engineered lower eukaryotic host strains deficient in grr1 activity for recombinant protein
1002015029013510/15/15 Process for making agglomerates using acoustic mixing technology
1012015029032510/15/15 Liquid formulations for tnfr:fc fusion proteins
1022015029155810/15/15 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
1032015029156110/15/15 Substituted pyridone derivatives as pde10 inhibitors
1042015029162010/15/15 Glycosidase inhibitors and uses thereof
1052015029168310/15/15 Modified apol1 polypeptides
1062015028436810/08/15 Secondary alcohol substituted triazoles as pde10 inhibitors
1072015028437610/08/15 Mineralocorticoid receptor antagonists
1082015028437910/08/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1092015028438110/08/15 Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
1102015028438910/08/15 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
1112015028441110/08/15 Novel azabenzimidazole hexahydrofuro[e,2-b]furan derivatives
1122015028475310/08/15 Process for the preparation of an intermediate for an orexin receptor antagonists
1132015027465610/01/15 Glycosidase inhibitors and uses thereof
1142015027466410/01/15 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
1152015027467210/01/15 Substituted spiropiperidinyl compounds useful as gpr120 agonists
1162015027470810/01/15 Inhibitors of irak4 activity
1172015027471610/01/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1182015027473910/01/15 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1192015027475510/01/15 Compound diversification using late stage functionalization
1202015027476710/01/15 4'-substituted nucleoside reverse transcriptase inhibitors
1212015027522210/01/15 Crz1 mutant fungal cells
1222015026571509/24/15 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1232015026689509/24/15 Novel compounds that are erk inhibitors
1242015026689709/24/15 Hcv ns3 protease inhibitors
1252015025807409/17/15 Novel compounds that are erk inhibitors
1262015026073109/17/15 Antibodies, kit and detecting amyloid beta oligomers
1272015025075909/10/15 Composition for inhibition of cathepsin k
1282015025203309/10/15 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists
1292015025203409/10/15 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
1302015025334109/10/15 Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
1312015024690209/03/15 Substitued benzofuran compounds and methods of use thereof for the treatment of viral diseases
1322015024691709/03/15 Inhibitors of hepatitis c virus replication
1332015023986608/27/15 Triazolyl derivatives as syk inhibitors
1342015023242808/20/15 Substituted phenyl-spleen tyrosine kinase (syk) inhibitors
1352015023244708/20/15 Crystalline form of a reverse transcriptase inhibitor
1362015022536508/13/15 Indoline compounds as aldosterone synthase inhibitors
1372015022540208/13/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
1382015021809608/06/15 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
1392015021809708/06/15 Glycosidase inhibitors and uses thereof
1402015021814708/06/15 Glycosidase inhibitors and uses thereof
1412015021814908/06/15 Novel benzimidazole tetrahydrofuran derivatives
1422015021816408/06/15 Substituted naphthyridinedione derivatives as hiv integrase inhibitors
1432015021816908/06/15 3-aminocycloalkyl compounds as rorgammat inhibitors and uses thereof
1442015020942407/30/15 Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
1452015021068507/30/15 Novel azabenzimidazole tetrahydropyran derivatives
1462015021068707/30/15 N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
1472015020348707/23/15 Novel azabenzimidazole tetrahydrofuran derivatives
1482015020349607/23/15 Aliphatic spirolactam cgrp receptor antagonists
1492015020351207/23/15 Macrocyclic compounds as hiv integrase inhibitors
1502015019749007/16/15 Crystalline polymorphic forms of an antidiabetic compound
1512015019753107/16/15 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
1522015019757007/16/15 Anti-ilt5 antibodies and ilt5-binding antibody fragments
1532015019777207/16/15 Mammalian expression vector puhab
1542015019040207/09/15 Solid dosage formulations of an orexin receptor antagonists
1552015019143407/09/15 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
1562015019146107/09/15 Pyrazolyl derivatives as syk inhibitors
1572015019149507/09/15 Antidiabetic tricyclic compounds
1582015018250307/02/15 Mineralocorticoid receptor antagonists
1592015017553406/25/15 Alpha-7 nicotinic acetylcholine receptor modulators and uses therof-i
1602015017557506/25/15 Imidazolyl analogs as syk inhibitors
1612015017560906/25/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
1622015016648606/18/15 Substituted diazine and triazine spleen tyrosine kinease (syk) inhibitors
1632015016649006/18/15 Mineralocorticoid receptor antagonists
1642015016652006/18/15 Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
1652015015893506/11/15 Protective vaccine based on staphylococcus aureus sa2493 protein
1662015015099006/04/15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
1672015015212706/04/15 Permeable glycosidase inhibitors and uses thereof
1682015014733705/28/15 Crystalline anti-human il-23 antibodies
1692015014824605/28/15 Surface anchored light chain bait antibody display system
1702015014832705/28/15 Substituted pyridine spleen tyrosine kinase (syk) inhibitors
1712015013998605/21/15 Ilt3 binding molecules and uses therefor
1722015014142805/21/15 Trka kinase inhibitors, compositions and methods thereof
1732015014144405/21/15 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
1742015012644305/07/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1752015012649305/07/15 Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
1762015011939404/30/15 Insulin-like growth factor-1 receptor inhibitors
1772015011186604/23/15 Cyclic amine substituted heterocyclic cetp inhibitors
1782015011187704/23/15 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
1792015011191404/23/15 Spirolactam cgrp receptor antagonists
1802015010445304/16/15 Fdf03 antibodies and uses thereof
1812015010446504/16/15 Il-19 as a biomarker of tslp treatment
1822015010531704/16/15 Glucose-responsive insulin conjugates
1832015010535404/16/15 Heterocyclic aspartyl protease inhibitors
1842015009989104/09/15 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
1852015009971504/09/15 Formulations of acadesine
1862015009971904/09/15 Cathepsin cysteine protease inhibitors
1872015009972904/09/15 Inhibitors of the renal outer medullary potassium channel
1882015009977104/09/15 Pyridine cgrp receptor antagonists
1892015009339804/02/15 Methods and compositions for treating or preventing cancer
1902015008390603/26/15 Biomarkers for monitoring intervention therapies for diabetes
1912015008764103/26/15 Heterocyclic cgrp receptor antagonists
1922015008783203/26/15 Process for making beta 3 agonists and intermediates
1932015007899603/19/15 Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
1942015007903103/19/15 Use of pegylated il-10 to treat cancer
1952015008059803/19/15 Asymmetric synthesis for preparing fluoroleucine alkyl esters
1962015006419203/05/15 Mammalian cell surface antigens; related reagents
1972015005619102/26/15 Igf1 biomarker for igf1r inhibitor therapy
1982015005122702/19/15 Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
1992015005124802/19/15 Imidazolyl methyl piperidine t-type calcium channel antagonists
2002015004425002/12/15 Vaccines against clostridium difficile comprising recombinant toxins
2012015004534602/12/15 Selective glycosidase inhibitors and uses thereof
2022015004557502/12/15 Process for preparing fluoroleucine alkyl esters
2032015003849002/05/15 Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
2042015003849802/05/15 Thrombin inhibitors
2052015003850202/05/15 Isoxazolopyridine orexin receptor antagonists
2062015003870702/05/15 Process for making cgrp receptor antagonists
2072015003171301/29/15 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
2082015003171601/29/15 Piperidinone carboxamide azaindane cgrp receptor antagonists
2092015003189101/29/15 Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
2102015002080601/22/15 Dry powder inhaler for delivering multipe agglomerate formulations
2112015002395201/22/15 Anti-addl monoclonal antibody and uses thereof
2122015002407101/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
2132015002504601/22/15 Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
2142015001768601/15/15 Methods for reducing mannosyltransferase activity in lower eukaryotes
2152015001839901/15/15 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2162015001056401/08/15 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
2172015000460801/01/15 Monocyte-derived nucleic acids and related compositions and methods
2182015000533001/01/15 Piperidinone carboxamide azaindane cgrp receptor antagonists
2192014037726012/25/14 Protective vaccine based on staphylococcus aureus sa2074 protein
2202014037849312/25/14 Fused bicyclic oxazolidinone cetp inhibitor
2212014037002512/18/14 Uses of mammalian cytokines and agonists; related reagents
2222014037113812/18/14 Inhibitors of hepatitis c virus replication
2232014034997211/27/14 Substituted pyrimidines
2242014034884111/27/14 Anti-gitr antibodies
2252014034999811/27/14 Pyrrolopyrimidines as janus kinase inhiitors
2262014035000211/27/14 Imidazopyridin-2-one derivatives
2272014034307111/20/14 Compositions and methods for treating cancer
2282014033619611/13/14 Phosphoric acid salts of sitagliptin
2292014032927611/06/14 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
2302014032351910/30/14 Heterocyclic compounds as b-raf inhibitors for treatment of cancer
2312014029620210/02/14 Substituted piperidinyl compounds useful as gpr119 agonists
2322014029622110/02/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
2332014029622210/02/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
2342014027501709/18/14 Cgrp receptor antagonists
2352014025681809/11/14 Nano-suspension process
2362014024428908/28/14 Cold storage system for storing pharmaceutical product containers
2372014023429608/21/14 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
2382014023430108/21/14 Modulation of pilr to treat immune disorders
2392014023553708/21/14 N-glycosylated insulin analogues
2402014022562708/14/14 Device for calibrating and verifying the integrity of resistivity-based sensing probes
2412014022722308/14/14 Pegylated interleukin-10
2422014022725008/14/14 Stable formulations of antibodies to tslp
2432014022729008/14/14 Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
2442014022729208/14/14 Anti-mcam antibodies and associated methods of use
2452014022002708/07/14 1d05 pcsk9 antagonists
2462014022138308/07/14 Cetp inhibitors
2472014021241207/31/14 Use of il-33 antagonists to treat fibrotic disease
2482014020656307/24/14 Biomarkers for psoriasis
2492014020664007/24/14 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE